Microba Life Sciences Limited (ASX: MAP) - Share Price
Current share price for MAP : $0.042 0.002 (4.55%)+
Microba Life Sciences Limited (MAP), an ASX-listed company, is a Company that is engaged in microbiome testing, supplements and analysis services as well as developing new pathology services, therapeutics and diagnostics based on the human gut microbiome.
MAP General Information +
| ASX Code | MAP |
| Website | N/A |
| Industry/Sector | Health Care Services |
| Market Cap ($M) | 29 |
| MAP Share Price | $0.042 |
| Day High | $0.045 |
| Day Low | $0.042 |
| Last Close | $0.044 |
| MAP Share Price Movement | $0.00 ( 4.55% ) |
Prices as at 16:35, 21 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Microba Life Sciences Limited (MAP) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Microba Life Sciences Limited (MAP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Microba Life Sciences Limited (MAP) price-sensitive announcements
MAP - Q4 FY26 Quarterly Investor Presentation & Webinar
Microba Life Sciences Limited reported substantial growth in its core testing services for
Microba Life Sciences Limited (MAP)
16 Jul 2026 | 9:12 AM
16 Jul 2026 | 9:12 AM
MAP - Q4 FY26 Quarterly Activities Report & Appendix 4C
Microba Life Sciences Limited reported strong growth in Q4 FY26, achieving a record core t
Microba Life Sciences Limited (MAP)
16 Jul 2026 | 9:03 AM
16 Jul 2026 | 9:03 AM
MAP - Disclosure Document - Prospectus
Microba Life Sciences Limited is undertaking a capital raising effort via a Placement and
Microba Life Sciences Limited (MAP)
19 Jun 2026 | 9:09 AM
19 Jun 2026 | 9:09 AM
MAP - Reinstatement to Quotation
On 12 June 2026, Microba Life Sciences Limited (ASX: MAP) announced the reinstatement of i
Microba Life Sciences Limited (MAP)
12 Jun 2026 | 9:46 AM
12 Jun 2026 | 9:46 AM
Microba Life Sciences Limited (MAP) Recent ASX Announcements
MAP Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$19.41 | -$4.30 | -10.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$19.94 | -$4.90 | 27.60% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$12.68 | -$3.80 | -21.40% | 0.00 | 0.00 | 0.00% | 0.0% |
MAP Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Australian Clinical Labs Limited (ACL) | $440M | -0.0336 | 0.0000 | 0.0000 | 13.0315 | 0.0000 | 0.0000 | 5.30% | 0.00% | 0.00% |
| Healius Limited (HLS) | $272M | -4.7068 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Integral Diagnostics Limited (IDX) | $783M | -1.3095 | 0.5666 | 0.1667 | 27.4151 | 17.5000 | 15.0000 | 3.10% | 3.81% | 3.33% |
| Microba Life Sciences Limited (MAP) | $31M | -0.1091 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Sonic Healthcare Limited (SHL) | $10,814M | 0.0625 | 0.1134 | 0.1484 | 20.5061 | 18.4175 | 16.0375 | 4.89% | 5.00% | 5.05% |
MAP Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Pasquale (Paddy) Rombola | Non-Executive Chairman, Non-Executive Director | 23 Jun 2017 |
| Professor Ian Hector Frazer | Non-Executive Deputy Chairman, Non-Executive Director | 31 Jan 2017 |
| Professor Gene William Tyson | Non-Executive Director | 31 Jan 2017 |
| Ms Jacqueline Fernley | Non-Executive Director | 8 Sep 2022 |
| Mr Stephane Chatonsky | Non-Executive Director | 20 Nov 2025 |
Microba Life Sciences Limited (MAP) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 17 Sep 2025 | BUND, Richard | Sell | Indirect Shares | 690,290 | $0.082 | $56,672.810 |
| 10 Sep 2025 | BUND, Richard | Sell | Indirect Shares | 1,829,460 | $0.086 | $156,541.350 |
| 13 Aug 2025 | ROMBOLA, Pasquale (Paddy) | Issued | Indirect Shares | 600,000 | $0.090 | $54,000.000 |
See all changes in directors' interest & trades for Microba Life Sciences Limited (MAP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
MAP Management
| Name | Position |
|---|---|
| Luke Reid | Chief Executive Officer |
| James Heath | Chief Financial Officer,Company Secretary |
MAP Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Microba Life Sciences Limited (MAP). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 98,597,402 (19.14%) | Sonic Healthcare Limited |
| 69,378,634 (13.47%) | Perennial Value Management |
| 35,336,905 (6.86%) | Thorney Investment Group |
| 33,480,799 (6.50%) | SA Microba Holdings Pty Ltd |
MAP Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 16 October 2026 | Report (Annual) |
| 25 August 2026 | Report (Annual) |
| 25 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
